Date post: | 28-Mar-2015 |
Category: |
Documents |
Upload: | janessa-caulder |
View: | 213 times |
Download: | 0 times |
Biomediq
Biomedical Image Quantification www.biomediq.com
Biomediq
Personalized Breast cancer ScreeningMads Nielsen
Biomediq
Image Group
Biomediq
Image Group
Biomediq
Image Group
Biomediq
Image Group
Biomediq
Image Group
Biomediq
Image Group
Biomediq
Image Group
Biomediq
Motivation and summary
In the western world women are mammography screened for breast cancer differentiated on age only using more than 100.000.000 mammograms per year.
Risk profiling may be used to personalize screening frequency and/or technology to reduce cost and increase detection rate.
Breast density may provide an essential risk profiling tool.
We present the Breast Cancer Risk Meter based on density and mammographic breast tissue texture doubling the risk segregation compared to breast density alone.
Patented technology is using the screening mammogram to automatically asses the 4 year risk of breast cancer.
Biomediq
Participants
Biomediq A/S, Mads Nielsen• Management• Image analysis• Prototype development
DIKU, Chrstian Igel• Learning on massive data• Online learning
Capitol Region Screening Program, Ilse Vejborg• Data collection• Clinical testing
Department of Public Helath, Elsebeth Lynge• Risk modeling• Health economics
Biomediq
BIRADS Examples of the 4 categories
1 2 3 4
Biomediq
Method: BC Risk Meter
• Assess local pixel image structures [1]
• Match these to database of structures with known outcome (4y BC diagnosis) [2]
• Decide category for each pixel (e.g. healthy/4y BC diagnosis)
• Integrate local decisions to global score of the image
• Combine this with age and density into a risk estimate
1
2
Biomediq
Local Image Structure
Local Image Features
Biomediq
Method 3: Examples of density scores
Low Medium High
Biomediq
Clinical studies overview
S1: • Purpose: to demonstrate risk segregation ability• Materials: 245 cases/250 controls form the Dutch screening program. • Digitized film 2-4 year prior to diagnosis. • Result: risk segregation capability adds to percentage densityS2: • Purpose: to independently verify sensitivity and demonstrate robustness• Materials: 226 cases/442 controls form the Minnesota Cohort.• Digitized film 3-6 year prior to diagnosis• Result: adds robustly a factor of two to risk segregation odds ratioS3: • Purpose: to demonstrate robustness to modality and estrogen receptor status• 145 cases/423 controls from the Pennsylvania Cohort.• Direct Digital Mammography on contralateral breast including estrogen
receptor status.• Result: verifies robustness to modality and shows relation to ER status
Biomediq
S1: Breast cancer risk study
* Non-parametric
Method AUC p*
2 BI-RADS 0.58 < 10-2
3 Percentage 0.60 < 10-4
4 BC MTR 0.63 < 10-8
5 Aggregate 3+4 0.66 < 10-12
245 cancer cases (123 interval cancers and 122 screen detected) and 250 age-matched controls from the Dutch breast cancer screening program
Area under the ROC curve seperating cancers and controls
Biomediq
S2: Breast cancer validation study
S2: Mammograms 3-6 years prior to diagnosisControls(N=442) Cases(N=226) P-value
Age 54.8 ± 10.5 55.8 ± 10.6 0.28BMI 27.9 ± 6.6 27.9 ± 5.5 0.96PD 18.4 ± 14.7 22.0 ± 15.4 0.003
S1: Mammograms 2-4 years prior to diagnosis
Controls(N=250) Cases(N=245) P-valueAge 61.3 ± 6.4 61.7 ± 8.8 0.19PD 13.2 ± 10.2 16.9 ± 11.1 <0.001
Adjusted for BMI, Age, Menopause, HRT
PD 0.61
BC MTR 0.60
PD + BC MTR 0.66
Result of recognizing texture from S1 in S2
Biomediq
S3: Direct Digital Mammography
Examination at time of diagnosis, but from the unaffected mammogram.111 ER+ cases, 34 ER- cases, 423 controls.Differentiation of receptor status is based on recognition of texture in mammograms of known status.
Cancer vs control:
Separation of ER+ and ER-
AUC p-value
PD 0.56 <0.05
BC MTR 0.64 <0.001
PD + BC MTR 0.65 <0.001
AUC p-value
PD 0.51 NS
BC MTR 0.64 <0.05
PD + BC MTR 0.70 <0.001
Biomediq
Simple simulation of BC MTR personalization of screening
PD is used for referral to high risk programs. PD is published to be expedient for screening frequency personalization.
These simulation are based on S1 and the 4 year prognosis instead of the relevant 2 year prognosis
Whenever 100,000 women are screened using a recall rate of app. 2%- 462 cancers will be detected- 189 cancers will not be detected but show before next round
By excluding 20 % of the women with lowest score in next round- 16 cancers extra will show as interval cancers- This is less than half the rate as in normal screening
Hence, the women not screened in next round will have the half false negative rate compared to whole population now.
By referring 10% to high risk analysis- 42 % of the interval cancers will be in this group
Biomediq
Breast cancer technical details
New coordinate system with anatomical orientation
Biomediq
Breast cancer technical details
Features used are:- 3 jet- Horizontal heterogenity at scales 1 mm, 2mm, 4mm, 8mm- Posisition
kNN-classification, k=100
20 X 1000 random points per image, and SFS of features = 20 committees
Fusion of 20.000 x 100 NN by average
Biomediq
Project content
Retrospective study of all 2011 cancers at all time points8 x 4 x 2 x 360 images
Prospective study of all women screened in 2012-20152 x 4 x 160,000 images of 80 Mb each
Machine learning on massive data
Building a prototype
Biomediq
Prototype
Biomediq
Project conclusion
Will this technology make it possible to increase the early detection rate and save ressources at the same time?